FindMyKOL
Clinical trialNCT04216589CompletedPhase 2Interventional

Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)

NCT04216589 is a phase 2 interventional trial sponsored by National Institute of Allergy and Infectious Diseases (NIAID). As of 21 Nov 2026, it is completed. It studies Semaglutide in HIV Infections and Non-Alcoholic Fatty Liver Disease. The registry lists an enrollment of 51 participants at 9 sites in 2 countries. The registry lists a start date of 19 Feb 2021 and a primary completion date of 16 Mar 2023. 2 of its registered investigators have a FindMyKOL profile.

SponsorNational Institute of Allergy and Infectious Diseases (NIAID) →Enrollment51HIV InfectionsNon-Alcoholic Fatty Liver Disease
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT04216589
FieldValue
Registry IDNCT04216589
StatusCompleted
PhasePhase 2
Study typeInterventional trial
Lead sponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Enrollment51
Registered sites9
Countries2
ConditionsHIV Infections and Non-Alcoholic Fatty Liver Disease
DrugsSemaglutide
Start19 Feb 2021
Primary completion16 Mar 2023
Study completion15 Sept 2023
Last update posted1 Oct 2024

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study was to evaluate the effects of semaglutide on intra-hepatic triglyceride (IHTG) content in people living with HIV (PLWH), central adiposity, insulin resistance or pre-diabetes, and hepatic steatosis.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Alabama, United States1 site
  • Alabama Crs (site Id: 31788)

    Birmingham

Colorado, United States1 site
  • University of Colorado Hospital Crs (site Id: 6101)

    Aurora

Maryland, United States1 site
  • Johns Hopkins University Crs

    Baltimore

Massachusetts, United States1 site
  • Massachusetts General Hospital Crs (mgh Crs) (site Id: 101)

    Boston

Ohio, United States2 sites
  • Cincinnati Clinical Research Site (site Id: 2401)

    Cincinnati

  • Ohio State University Crs (site Id: 2301)

    Columbus

Texas, United States1 site
  • Houston Aids Research Team Crs (site Id: 31473)

    Houston

Washington, United States1 site
  • University of Washington Aids Crs (site Id: 1401)

    Seattle

Brazil1 site
  • Instituto de Pesquisa Clinica Evandro Chagas (ipec) Crs (site Id: 12101)

    Rio de Janeiro

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashington: 1 siteWA1MontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusetts: 1 siteMA1Rhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhio: 2 sitesOH2PennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMaryland: 1 siteMD1DelawareDEArizonaAZUtahUTColorado: 1 siteCO1KansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabama: 1 siteAL1GeorgiaGAHawaiiHITexas: 1 siteTX1FloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Outside the United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT04216589

Each answer restates registry values shown on this page.

What is NCT04216589?

NCT04216589 is a phase 2 interventional trial sponsored by National Institute of Allergy and Infectious Diseases (NIAID). It studies Semaglutide in HIV Infections and Non-Alcoholic Fatty Liver Disease.

Who leads NCT04216589?

The registry names Jordan E. Lake, MD, MSc (study chair, Houston AIDS Research Team CRS) and Kristine Erlandson, MD, MS (study chair, University of Colorado Hospital CRS) as overall officials.

Where does NCT04216589 run?

The registry lists 9 sites in 2 countries. Most sites are in these countries: United States (8) and Brazil (1).

Which drugs does NCT04216589 study?

The registered drug and biological interventions are Semaglutide.

When did NCT04216589 end?

The registry lists a primary completion date of 16 Mar 2023 and a study completion date of 15 Sept 2023. The sponsor last updated the record on 1 Oct 2024.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.